[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
Sept 1982

Lithium Carbonate and Imipramine in the Prophylaxis of Unipolar and Bipolar II IllnessA Prospective, Placebo-Controlled Comparison

Author Affiliations

From Long Island Jewish-Hillside Medical Center, Glen Oaks, NY (Drs Kane, Ramos-Lorenzi, and Nayak and Ms Howard), New York State Psychiatric Institute (Dr Quitkin), and Mount Sinai Medical Center (Dr Rifkin), New York.

Arch Gen Psychiatry. 1982;39(9):1065-1069. doi:10.1001/archpsyc.1982.04290090053011
Abstract

• Twenty-seven patients with recurrent unipolar depression and 22 with bipolar II illness in remission for at least six months were randomly assigned on a double-blind basis to treatment regimens using lithium carbonate, imipramine hydrochloride, lithium carbonate plus imipramine, or placebo. Lithium carbonate was found to help prevent depressive relapse among patients with unipolar disease, and relapse of any type among those with bipolar II disease. No effect or interaction of imipramine was found in either group. These results add to a growing body of data that suggest the usefulness of lithium carbonate in the prophylaxis of unipolar depressive illness. The relative usefulness of lithium carbonate and imipramine requires further study.

×